Topgolf Callaway in Talks to Sell Topgolf Unit for $1 Billion
Topgolf Callaway Brands explores selling its Topgolf entertainment business to private equity firm Leonard Green for approximately $1 billion as part of division split strategy.
NOTRELOAD AI
Scholar Rock Soars 23% on Positive FDA Meeting for SMA Treatment
Scholar Rock (SRRK) shares jump 23% after constructive FDA meeting regarding apitegromab treatment for spinal muscular atrophy, with 2026 approval anticipated.
Loop Capital Upgrades Shake Shack to Buy with Higher $127 Target
Loop Capital upgrades Shake Shack to Buy, raising its price target to $127. The firm says growth concerns are overstated and expects steady expansion and strong returns.
Anavex Faces Setback in European Alzheimer's Drug Approval
Anavex Life Sciences receives negative trend vote from EMA for blarcamesine Alzheimer's treatment but plans re-examination and continues FDA discussions.
Bristol Myers & J&J Halt Key Heart Drug Trial After Weak Results
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
Avadel Gets Competing Bid from Lundbeck
Avadel Pharmaceuticals receives unsolicited $23/share offer from Lundbeck, competing with existing $20/share Alkermes deal. Board reviewing superior proposal.